Qiang Su

Mr. Qiang Su

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QSQiang Su
Qiang Su
YZYumeng Zhang
Yumeng Zhang
YSYuanhao Sui
Yuanhao Sui
LSLihua Sun
Lihua Sun
DZDawei Zhang
Dawei Zhang
The issue of regional disparities in medical resources and insurance benefits is notably prevalent in China. As a result, seeking medical treatment across regions has emerged as a focal point of health reform efforts in recent years. This study examines the impact of outpatient settlement for cross-regional medical treatment on healthcare choices by the floating population who live and work in regions different from their registered residence. Using data from the China Family Panel Studies (CFPS), this study conducts an empirical analysis through Propensity Score Matching and Difference-in-Differences (PSM + DID). The analysis included a sample of 3,019 floating population from 2012 to 2020. The findings indicate that they are significantly more inclined to select advanced medical institution (coefficient = 0.252, p < 0.05) due to the influence of the policy. Furthermore, heterogeneity analysis reveals that this policy primarily affects the labor force (coefficient = 0.268, p < 0.05) and urban residents (coefficient = 0.286, p < 0.05) within the floating population. Ultimately, the outpatient settlement for cross-regional medical treatment affects the floating population to seek care at advanced medical institution, which conflicts with the objectives of the hierarchical medical system. Policymakers should enhance communication to ensure better coordination between these policies.

31 August 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
YZYumeng Zhang
Yumeng Zhang
MYMinghao Yang
Minghao Yang
QSQiang Su
Qiang Su
YSYuanhao Sui
Yuanhao Sui
LSLihua Sun
Lihua Sun
Objectives: Patients with rare diseases in China face extremely high medical expenses. The current coverage framework remains inadequate in terms of coverage depth and proactive risk control, underscoring an urgent need for institutional reform. Methods: This study employs a policy content analysis approach to review the current landscape of rare disease protection in China. Drawing on risk management theory and the health capital model, it constructs an analytical framework to examine potential institutional reforms through the lens of risk response pathways and the efficiency of health investment. Results: The findings reveal that basic medical insurance (BMI) provides limited financial protection for patients with rare diseases. Among China’s 31 provincial-level administrative centers, 24 have set general outpatient reimbursement ceilings under the urban and rural resident basic medical insurance (URRBMI) at 1000 RMB or less. In comparison, 24 cities have set outpatient reimbursement limits under the urban employee basic medical insurance (UEBMI) at 6000 RMB or less. The security system relies predominantly on the BMI, while supplementary mechanisms have failed to provide effective support or continuity in coverage. Current policies are generally reactive, with coverage typically triggered only after a confirmed diagnosis and often lacking early intervention or preventive strategies. Conclusions: China’s rare disease security system urgently requires structural improvements in coverage depth and proactive risk management. The proposed Dedicated Insurance Scheme for Rare Diseases (DISRD) presents a feasible and sustainable model for China’s multi-tiered system of securing rare diseases. It provides valuable institutional insights for other countries and regions seeking to build public health systems with proactive risk control capabilities.

16 October 2025 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
QSQiang Su
Qiang Su
XPXiaochen Peng
Xiaochen Peng
YZYumeng Zhang
Yumeng Zhang
LSLihua Sun
Lihua Sun
Health utility measurement is critical for cost-utility analysis (CUA). However, clinical studies often lack direct utility data, and methods of measuring health utility vary across different periods and regions, resulting in missing utility information. Mapping, a method employed to infer utility when direct utility data is absent, has been widely applied in recent years but still faces challenges. This systematic review evaluates the current landscape, trends, and limitations of mapping studies and provides recommendations for improving study design and reporting standards. A literature search was conducted in PubMed, Web of Science, and the HERC Database of Mapping Studies from 2018 to 2024. The study extracted information from the included studies and performed quality assessments based on existing mapping guidelines. One hundred thirty-one studies were included, 92 focused on Mapping as the primary objective, five were reviews, 13 focused on methodology, and 21 focused on economic evaluation. The source measure, target measure, and models in mapping functions development remain EORTC-QLQ-C30 (n = 13), EQ-5D (n = 79), and OLS (n = 93). Studies now use larger sample sizes and a higher proportion of response Mapping, and model applications have increased in diversity. However, 32 studies still lack conceptual overlap analysis, and only 16 studies with repeated measurements addressed its issue. Additionally, two studies did not report the region of the sample and value set, while 27 had inconsistencies between the two regions. In the last seven years, mapping studies have improved sample size, model application, and result reporting. However, limitations remain in analysing conceptual overlap, ensuring alignment between the sample and value set regions, and processing repeated measurements. To advance the quality of mapping studies, it is necessary to update mapping guidelines and ensure that all mapping functions are developed in compliance with them.

21 October 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
MYMinghao Yang
Minghao Yang
YZYumeng Zhang
Yumeng Zhang
QSQiang Su
Qiang Su
YSYuanhao Sui
Yuanhao Sui
LSLihua Sun
Lihua Sun
Background: The continuous expansion of the National Reimbursement Drug List has led to an increasing cost disparity among alternative drugs for the same indications. Under the current proportional reimbursement mechanism, choosing higher-cost treatments often results in higher compensation. Given the lack of empirical evidence on whether income affects the medication choices of insured individuals in the Chinese context, this study aims to evaluate the impact of income levels on drug selection, providing a basis for optimizing the medical insurance reimbursement policy. Methods: This study extracts data from hospitalized patients enrolled in basic medical insurance from the China Health and Retirement Longitudinal Study (CHARLS) database and preprocesses it in Excel. Subsequently, SPSS is used to conduct descriptive statistics, difference analysis, correlation analysis, and regression analysis on the processed data to explore the impact of income levels on drug selection. Results: After controlling for length of hospitalization and hospitalization costs, the regression coefficient for urban employee basic medical insurance participants is β = 0.505 (p < 0.01), and the regression coefficient for new rural cooperative medical insurance participants is β = 0.195 (p < 0.01). This means that, regardless of whether participants are enrolled in urban employee basic medical insurance or new rural cooperative medical insurance, an increase in income will lead to higher hospitalization drug costs. Conclusions: Compared to low-income insured individuals, high-income participants in the basic medical insurance are more likely to choose higher-cost drugs among alternatives, which leads to unfair reimbursement under the current proportional reimbursement system.